Known targets — ChEMBL curated mechanism
ACVR1ADORA1ADORA2AADORA2BADORA3ESR1ESR2FLT3GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSC1HRH1HTR7IDH1IDH2IRAK1JAK1JAK2JAK3MEN1OPRM1P2RX3PDE5ASCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASIGMAR1SLC6A2SYKTACR1TOP2ATYK2
The experimentally established mechanism targets of Citric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 known ✓ | O00255 | 1/20 | 0.42 |
| ▸ | MTNR1A | P48039 | 14/20 | 0.57 |
| ▸ | MTNR1B | P49286 | 14/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | APEX1 | P27695 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Citric Acid SCHEMBL3253261 | 0.91 | MTNR1A (0.59) | MTNR1AMTNR1BCYP1A2CYP2D6KDM4E | |
| Citric Acid SCHEMBL3248609 | 0.88 | MTNR1A (0.55) | MTNR1AMTNR1BCYP1A2CYP2D6KDM4E | |
| SCHEMBL3257337 | 0.87 | MTNR1A (0.63) | MTNR1AMTNR1BCYP1A2CYP2D6KDM4E | |
| Citric Acid SCHEMBL3253262 | 0.86 | MTNR1A (0.58) | MTNR1AMTNR1BCYP1A2CYP2D6KDM4E | |
| Citric Acid SCHEMBL3248466 | 0.84 | MTNR1A (0.57) | MTNR1AMTNR1BCYP1A2CYP2D6KDM4E | |
| Oxalic Acid SCHEMBL3250917 | 0.80 | MTNR1A (0.67) | MTNR1AMTNR1BCYP1A2CYP2D6KDM4E | |
| Maleic Acid SCHEMBL3250853 | 0.78 | MTNR1A (0.64) | MTNR1AMTNR1BCYP1A2CYP2D6KDM4E | |
| SCHEMBL3244549 | 0.77 | MTNR1A (0.66) | MTNR1AMTNR1BCYP1A2CYP2D6KDM4E | |
| Malic Acid SCHEMBL3264697 | 0.77 | MTNR1A (0.60) | MTNR1AMTNR1BCYP1A2CYP2D6KDM4E | |
| Hydrochloric Acid SCHEMBL3245450 | 0.77 | MTNR1A (0.64) | MTNR1AMTNR1BCYP1A2CYP2D6KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1537113-B9 | ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2010-05-26 | — | — | EP | claimed |
| EP-1537113-B1 | ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2009-10-07 | — | — | EP | claimed |
| US-7297711-B2 | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2007-11-20 | — | — | US | claimed |
| US-20050203103-A1 | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2005-09-15 | — | — | US | claimed |
| EP-1537113-B9 | ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2010-05-26 | — | — | EP | disclosed |
| EP-1537113-B1 | ARYLALKYL INDOLES HAVING SEROTONIN RECEPTOR AFFINITY USEFUL AS THERAPEUTIC AGENTS, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | SUVEN LIFE SCIENCES LTD (IN) | 2009-10-07 | — | — | EP | disclosed |
| US-7297711-B2 | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2007-11-20 | — | — | US | disclosed |
| US-20050203103-A1 | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | SUVEN LIFE SCIENCES LIMITED (IN) | 2005-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050203103-A1 | Arylalkyl indoles having serotonin receptor affinity useful as therapeutic agents, process for their preparation and pharmaceutical compositions containing them | TPH1, HTR1A, HTR7 | MEN1 3998/4885MTNR1A 76/4885MTNR1B 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.